Agenus reports 39% of patients alive at two-years with bot/bal across multiple refractory solid tumors at esmo 2025

Lexington, mass.--(business wire)---- $agen #bal--agenus inc. (nasdaq: agen), a leader in immuno-oncology innovation, today announced new data from its botensilimab (bot), a multifunctional, fc-enhanced ctla-4 antibody and balstilimab (bal), a pd-1 inhibitor, combination demonstrating durable survival across multiple cancer types in late-stage patients who have limited treatment options. the results, featured in an oral session at the european society for medical oncology (esmo) congress 2025 in berlin, germa.
AGEN Ratings Summary
AGEN Quant Ranking